Evidence map›Paper›PMID 41485922›Full record

ArticleInternal medicine (Tokyo, Japan)2026

Sofosbuvir/Velpatasvir in Chronic Hepatitis C, Compensated and Decompensated Cirrhosis, and Retreatment Settings.

Hitomi Takada, Nobuharu Tamaki, Hironori Ochi, Nami Mori, Keiji Tsuji, Toshifumi Tada, Shinichiro Nakamura, Junichi Toshimori, Naoki Yoshioka, Hirotaka Arai and 21 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Hitomi TakadaDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan.
Nobuharu TamakiDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan.
Hironori OchiCenter for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Japan.
Nami MoriDepartment of Gastroenterology, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Japan.
Keiji TsujiDepartment of Gastroenterology, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Japan.
Toshifumi TadaDepartment of Gastroenterology, Japanese Red Cross Society Himeji Hospital, Japan.
Shinichiro NakamuraDepartment of Gastroenterology, Japanese Red Cross Society Himeji Hospital, Japan.
Junichi ToshimoriDepartment of Gastroenterology, Japanese Red Cross Okayama Hospital, Japan.
Naoki YoshiokaDepartment of Gastroenterology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Japan.
Hirotaka AraiDepartment of Gastroenterology, Japanese Red Cross Maebashi Hospital, Japan.
Hideki FujiiDepartment of Gastroenterology, Japanese Red Cross Kyoto Daiichi Hospital, Japan.
Chitomi HasebeDepartment of Gastroenterology, Japanese Red Cross Asahikawa Hospital, Japan.
Toshimitsu MurohisaDepartment of Gastroenterology, Japanese Red Cross Ashikaga Hospital, Japan.
Eisuke OkamotoDepartment of Gastroenterology, Masuda Red Cross Hospital, Japan.
Masahiko KondoDepartment of Gastroenterology, Japanese Red Cross Otsu Hospital, Japan.
Hiroyuki MarusawaDepartment of Gastroenterology and Hepatology, Japanese Red Cross Osaka Hospital, Japan.
Naohito UrawaDepartment of Hepatology, Japanese Red Cross Ise Hospital, Japan.
Takuto YoshiokaDepartment of Hepatology, Japanese Red Cross Takatsuki Hospital, Japan.
Hideo YoshidaDepartment of Hepatology, Japanese Red Cross Medical Center, Japan.
Ryoichi NaritaDepartment of Gastroenterology, Oita Red Cross Hospital, Japan.
Takehiro AkahaneDepartment of Gastroenterology, Japanese Red Cross Ishinomaki Hospital, Japan.
Atsunori KusakabeDepartment of Gastroenterology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Japan.
Michiko NonogiDepartment of Gastroenterology, Tokushima Red Cross Hospital, Japan.
Ryosuke ImadoDepartment of Gastroenterology and Hepatology, Takamatsu Red Cross Hospital, Japan.
Yasushi UchidaDepartment of Gastroenterology, Japanese Red Cross Matsue Hospital, Japan.
Takashi SatoDepartment of Gastroenterology, Japanese Red Cross Nasu Hospital, Japan.
Keisuke YokohamaDepartment of Gastroenterology, Tottori Red Cross Hospital, Japan.
Yoshihito KubotsuDepartment of Internal Medicine, Karatsu Red Cross Hospital, Japan.
Toru IshiiDepartment of Gastroenterology, Japanese Red Cross Akita Hospital, Japan.
Namiki IzumiDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan.
Masayuki KurosakiDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective Sofosbuvir/velpatasvir (SOF/VEL) has been approved for various stages of hepatitis C virus (HCV) infection; however, real-world data on Japanese patients remain limited. We evaluated the efficacy of SOF/VEL treatment in Japanese patients with chronic hepatitis, compensated cirrhosis, decompensated cirrhosis, and direct-acting antiviral (DAA) retreatment. Methods This multicenter prospective study enrolled 236 patients treated with SOF/VEL (with ribavirin for retreatment) at 21 Japanese institutions (chronic hepatitis, n=35; compensated cirrhosis, n=43; decompensated cirrhosis, n=134; undergoing DAA retreatment, n=24). The primary outcome was the sustained virologic response (SVR) rate at 24 weeks post-treatment (SVR24). In decompensated cirrhosis, liver function changes were assessed using the modified albumin-bilirubin (ALBI) score. Results The overall SVR24 rate was 97%, with SVR24 achieved in 100% of the patients with chronic hepatitis and compensated cirrhosis, 96% of those with decompensated cirrhosis, and 92% of those undergoing DAA retreatment. In the decompensated cirrhosis group, a significant improvement in the modified ALBI scores was observed from baseline to SVR24, and this improvement was sustained for two years after treatment. The proportion of patients with modified ALBI grades 1 or 2a increased from 5.2% at baseline to 23% at the end of treatment, 31% at SVR12, 35% at SVR24, 37% at 1 year, and 44% at 2 years post-treatment. Conclusion SOF/VEL has demonstrated high efficacy in all stages of hepatitis C, including patients with chronic hepatitis, compensated cirrhosis, decompensated cirrhosis, and prior DAA failure. The ability to achieve high efficacy at any stage of chronic hepatitis C is expected to improve the prognosis for a wide range of patients.

Indexed as

Antiviral AgentsCarbamatesHepatitis C, ChronicHeterocyclic Compounds, 4 or More RingsLiver CirrhosisSofosbuvirAgedBenzimidazolesBenzopyransDrug CombinationsDrug Therapy, CombinationFemaleHepacivirusHumansJapanMaleAntiviral AgentsBenzimidazolesBenzopyransCarbamatesDrug CombinationsHeterocyclic Compounds, 4 or More RingsSofosbuvirsofosbuvir-velpatasvir drug combinationhepatitis Cliver functionsofosbuvir/velpatasvirsustained virologic response

Identifiers

PMID41485922
PMCPMC13561563

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.